ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
6 |
21:20 |
21:20 |
ASX - By Stock
|
147
|
30K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
15 |
2.1K |
9 |
14:03 |
14:03 |
ASX - By Stock
|
15
|
2.1K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
15 |
2.1K |
4 |
13:56 |
13:56 |
ASX - By Stock
|
15
|
2.1K
|
4
|
|
ASX - By Stock
|
PAA |
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
15 |
2.1K |
2 |
12:18 |
12:18 |
ASX - By Stock
|
15
|
2.1K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
10K |
14 |
07:24 |
07:24 |
ASX - By Stock
|
61
|
10K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
10K |
11 |
06:42 |
06:42 |
ASX - By Stock
|
61
|
10K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
19 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
147
|
30K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
12 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
147
|
30K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
34 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
147
|
30K
|
34
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
11 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
147
|
30K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
11 |
2.9K |
15 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
11
|
2.9K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
14 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
147
|
30K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
10K |
30 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
61
|
10K
|
30
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
10K |
22 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
10K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
9 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
147
|
30K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
23 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
147
|
30K
|
23
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
11 |
2.9K |
7 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
11
|
2.9K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
12 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
147
|
30K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
18 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
147
|
30K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
adreamer
|
61 |
10K |
7 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
61
|
10K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
20 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
147
|
30K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
11 |
2.9K |
8 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
11
|
2.9K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
11 |
2.9K |
31 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
11
|
2.9K
|
31
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
21 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
147
|
30K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
147 |
30K |
26 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
147
|
30K
|
26
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
6 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
1 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
7 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
5 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
19 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
16 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
30 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
30
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
17 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
25 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
510
|
117K
|
25
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
25 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
510
|
117K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
adreamer
|
22 |
6.8K |
21 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
22
|
6.8K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
22 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
510
|
117K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
TOP 100 PAAO HOLDERS AS AT 31/05/24
|
|
adreamer
|
24 |
5.9K |
12 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
24
|
5.9K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
35 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
510
|
117K
|
35
|
|
ASX - By Stock
|
PAA |
Re:
TOP 100 PAAO HOLDERS AS AT 31/05/24
|
|
adreamer
|
24 |
5.9K |
6 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
24
|
5.9K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
21 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
510
|
117K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
adreamer
|
85 |
20K |
43 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
43
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
adreamer
|
85 |
20K |
16 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
18 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
510
|
117K
|
18
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
19 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
510
|
117K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
8 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
510
|
117K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
12 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
510
|
117K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
9 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
510
|
117K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
5 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
510
|
117K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
510 |
117K |
28 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
510
|
117K
|
28
|
|